INBRAIN Neuroelectronics ha compartido esto
We are #hiring at INBRAIN Neuroelectronics!
High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications. *FDA breakthrough Designation*
Enlace externo para INBRAIN Neuroelectronics
Barcelona, ES
INBRAIN Neuroelectronics ha compartido esto
We are #hiring at INBRAIN Neuroelectronics!
INBRAIN Neuroelectronics ha compartido esto
So proud of this dream teamwork!! We keep making unprecedented progress on Graphene BCI therapeutics! https://lnkd.in/d62Q4XS5
🚀 Breakthroughs in Brain-Computer Interfaces: INBRAIN Leads the Path with Graphene-Based Transistors 🚀 INBRAIN Neuroelectronics together with Institut Català de Nanociència i Nanotecnologia (ICN2) are revolutionizing BCI technology with their graphene-based transistors, a GphT-BCI project in progress since December 1, 2023. This innovative approach addresses the limitations of traditional metal electrodes, offering less invasive and more effective solutions extremely relevant in diseases such as Epilepsy, Stroke and general brain health. On July 1, 2024, the team got together to showcase the progress and celebrate the start of fabrication in 6-inch wafers, a crucial step towards mass production. With significant advancements in dedicated read-out electronics, this technology is moving swiftly from labs to clinical settings. Read the full article on project's website https://lnkd.in/dhRZsNCy
INBRAIN Neuroelectronics ha compartido esto
🌟 We're excited that our friends from Vsquared Ventures are once again partners of the Festival der Zukunft by 1E9 and Deutsches Museum, Jun 27-30, Munich! As the pioneer of European deep-tech investment, Vsquared is supporting entrepreneurs that push the boundaries of what's possible! The perfect match for our festival! On June 28 at 12:30 PM, Lise Rechsteiner, PhD, General Partner of Vsquared Ventures, will discuss "Revolutionizing Brain-Computer Interfaces with Graphene" with Carolina Aguilar, CEO of INBRAIN Neuroelectronics. Join us on June 27 at 4:00 PM for our VC Roundtable, "Scaling Up: The Future of European Venture Capital," featuring Dr.-Ing. Herbert Mangesius, General Partner of Vsquared and co-founder of 1E9, alongside Anke Gratz of DTCF | DeepTech & Climate Fonds, Ion Hauer of APEX Ventures, Gonzalo Pérez of Wayra Germany, and Lena Späth of First Momentum Ventures. And on June 28 at 4:00 PM, Herbert will moderate our panel, "Navigating Dual-Use Technologies in a New Geopolitical Era," with Rafaela Kraus from the University of the Bundeswehr Munich, Niclas Sundström of Worthwhile Capital Partners, Sven Weizenegger of Bundeswehr Cyber Innovation Hub and Joshua Western of Space Forge. Don't want to miss them and 150+ other great speakers? Find all information and tickets here: https://lnkd.in/d4qGrnZw #FdZ24 #FestivalderZukunft #DeepTech
An outstanding article today Financial Times highlighting the next generation of BCI for communication and BCI therapeutics we couldn't be more excited about what this decade will bring in helping people with neural related disorders!
The Financial Times - Clive Cookson, covers #braincomputer interfaces, highlighting both EU and US #bci companies. A detailed look and deep dive into some key topics for this space. 🧠🧠🧠 Other labs are developing more flexible and less invasive BCIs. Neurosoft Bioelectronics in Geneva is testing ultra-thin, soft electrodes deposited on silicone that wrap over the folds of the brain’s surface. Its technology has been tested successfully on three patients. INBRAIN Neuroelectronics’ graphene interface has similar selling points. It sits “on the cortex like a piece of cellophane without penetrating it,” says Carolina Aguilar, chief executive. Its first human trial is imminent. She sees Parkinson’s disease as InBrain’s first target, aiming to displace the “low density, low resolution” deep brain stimulation devices offered by medtech giants Boston Scientific and Medtronic. Some BCI companies are focusing on medical applications beyond disabled patients. Nicolas Vachicouras, Neurosoft chief executive, estimates that 60mn people worldwide have severe tinnitus, resulting in “severe depression and even suicide attempts, with no effective treatment available today”. The company’s research suggests that the cause is abnormal activity in the auditory cortex, giving the illusion of disturbing noise, which can be corrected with neuromodulation. Among the US companies, Synchron stands a good chance to be the first to get an BCI implant to market. Much like a stent, its device is inserted into a blood vessel and sits above the motor cortex, the part of the brain that controls movement. It has been tested in 10 patients so far and publication of final results is expected soon, followed by a larger clinical study which the company hopes will lead to FDA approval. Although the device is not as sensitive to neural activity as some competitors, Synchron chief executive Thomas Oxley says the company can achieve marketing approval more quickly with technology that does not require open brain surgery. “How can this technology improve people’s ability to live independently? That’ll be the marker of success,” he says. Sharing the article: https://lnkd.in/emTfKZww
INBRAIN Neuroelectronics ha compartido esto
Machine Learning for BCI therapeutics | Implantable Medical Devices | Brain Signal Processing | Neurotech | Data Science | PhD Imperial College London
Shout out to an insightful panel discussion at the AI for Good summit involving Ryan Field from Kernel, Andreas Forsland from Cognixion, Sid Koudier from Snap Inc. and (of course!) Carolina Aguilar (my CEO and colleague) at INBRAIN Neuroelectronics. Happy to have provided the materials for the INBRAIN's demo showcasing our ML development for high precision brain therapies. This wouldn't have been possible without Matteo Donega, Alejandro Pérez, Marina Saiz Alía, PhD and Aina Maull. such a great team behind! My personal takeaways from the discussion: 1 - Industry seems to have a more symbiotic and fruitful approach regarding the long-standing implantable VS non-implantable BCI confrontation. I moved to industry 3 years ago and by that time academy seemed to be finding a ultimate winner. I think both are valid approaches with different scopes and applications. A bike and a bus are both great means of transport and sometimes you'd like to take your bike in the bus. By confronting applications we may miss great symbiotic applications. So I lean towards the industry point of view. 2 - Following up on the previous. In my opinion, non-implantable BCI are great for point of care rapid and insightful brain function evaluation and life assistance. Their effectiveness lies on bigger coverage, both at the brain, clinical population and disease levels. If you need high precission and targeting specific brain structures and biomarkers for specific and refractive diseases continously and 24/7 implantable and miniaturised is the way forward. Both approaches complement each other very nicely in fact! How can we get the best out of each other inside and outside the clinical practice? 3 - Neurorights. This started as a question from the public and continued off-line with Karen Rommelfanger, PhD. We all agree that patient and stakeholder consent to their data usage should be the ground. But how do you factor in ethics in the design of those data systems and the human decisions in neurotrch organisations? Can an overarching ethical behaviour emerge in companies if all the individuals behave ethically? How can we do this in practice? It looks like a good start that people working in neurotech companies reflect on these questions! Looking forward to come next year with more and for more!
Advancing towards a real minimally invasive BCI therapeutics reality
🚀 Exciting progress from the 2024 MINIGRAPH General Assembly in Barcelona! Our consortium is advancing towards groundbreaking BCI therapeutics with new minimally invasive graphene brain implants and innovative robotic implantation procedure. Together, we're lighting up the path to revolutionary treatments for neurological disorders. 🌟 #Neuroelectronics #Innovation #HealthcareTech Read more at our project's website: https://lnkd.in/dUR_BFun
INBRAIN Neuroelectronics ha compartido esto
What to work in a life changing semiconductors development opportunity??? At INBRAIN Neuroelectronics we develop graphene semiconductors technology that powers intelligent precision BCI therapeutics at scale. Join us in lighting up the path to a better neural future!!!
We are looking for a Process Engineer to join our team. Interested? Get in touch with us! #hiring #thinfilm #cleanroom #graphene
What to work in a life changing semiconductors development opportunity??? At INBRAIN Neuroelectronics we develop graphene semiconductors technology that powers intelligent precision BCI therapeutics at scale. Join us in lighting up the path to a better neural future!!!
We are looking for a Process Engineer to join our team. Interested? Get in touch with us! #hiring #thinfilm #cleanroom #graphene
Next week is the week of AI for Good! Pablo O. leading our ML developments together with our CEO Carolina Aguilar will be demoing some of the AI work we are developing at INBRAIN Neuroelectronics in delivering real time precision BCI Therapeutics This is a highly anticipated event hosted by the International Telecommunication Union and United Nations Join us!! #ITUaiSummit
Seminconductors are of strategic importance for Spain, the EU and globally. They make crucial components of core emerging technologies such as AI, quantum and digitalization. In the case of INBRAIN Neuroelectronics its application in healthcare brings a revolutionary next gen of BCI therapeutics that allow more precise and effective neuro and bioelectronic therapies without the daring side effects of pharmacology. Jose Antonio Garrido, discusses how we are helping driving semiconductors leadership forward from Barcelona!
We are thrilled to present another episode of “In conversations with Barcelona & Partners”, an initiative where we give our partners the platform to share their insights on the current and future state of Barcelona’s technology and talent landscape. On this occasion, we had the opportunity of discussing with Jose Antonio Garrido, Deputy director of Institut Català de Nanociència i Nanotecnologia (ICN2) and Chief Scientific Officer and co-founder of INBRAIN Neuroelectronics, the importance of the semiconductor sector and the challenges it faces. One of the main challenges is the lab-to-fab gap, where highly advanced initiatives like #Innofab are crucial in bridging this gap. The Innofab project aims to build a pioneering clean room infrastructure, enabling the development of cutting-edge semiconductor technologies in an industrially relevant environment. This initiative has been launched in collaboration with key semiconductor stakeholders in Barcelona's R&D sector, Institut Català de Nanociència i Nanotecnologia (ICN2), Generalitat de Catalunya, the Institut de Microelectrònica de Barcelona (IMB-CNM, CSIC), ALBA Synchrotron, Universitat Autònoma de Barcelona, the ICFO and Barcelona & Partners. https://lnkd.in/dz2xNQkX
Última ronda
Financiación de deuda21.765.296,00 US$
Inversores
European Investment Bank